- Agilent Technologies ( NYSE: A ) on Monday said it would invest $725M to double its manufacturing capacity to produce nucleic acid-based therapeutics.
- The company has proposed the expansion through two new manufacturing lines at its facility in Frederick, Colo., and expects customer shipments from the new facility to begin in 2026.
- Therapeutic nucleic acids are short (DNA) and (RNA) molecules that serve as the active pharmaceutical ingredient for drugs targeting diseases such as cancer, cardiovascular disease, and rare and infectious diseases.
- "Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases," Agilent ( A ) said in a statement .
- Agilent ( A ) stock closed -2.9% at $147.67 on Friday.
For further details see:
Agilent to invest $725M to double manufacturing capacity for therapeutic nucleic acids